NCT04189276Unknown2 期
A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients
Tasly Tianjin Biopharmaceutical Co., Ltd.3 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2019年12月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 100
- 试验地点
- 3
- 主要终点
- All the observed or reported AEs (adverse events)
研究概览
简要总结
A multi-center, randomized, open-label, group controlled study to evaluate the safety and efficacy of T101 combined with nucleoside (acid) analogues in chronic hepatitis B patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all the following inclusion criteria to be enrolled in this study:
- •Patients between the ages of 18 and 60 years, male or female;
- •Body weight is no less than 45kg for female and no less than 50kg for male;
- •Meets the diagnosis and treatment standards of chronic hepatitis B in China's 2015 Guidelines for the Prevention and Treatment of Chronic Hepatitis B;
- •Currently, should have taken nucleoside (acid) analogues for 1 year or more;
- •HBV DNA<100 IU/ml; HBsAg is positive and no more than 3000 IU/ml；HBeAg is negative；
- •Be able to understand and sign informed consent.
排除标准
- •Patients with any of the following items will not be enrolled in this study:
- •Pregnant or lactating women; male or female who have planned to have children from the start of the study to sixth month after the end of the study.
- •Have received interferon treatment within 6 months prior to the screening;
- •Have taken strong immunomodulators (such as adrenocortical hormone, thymosin alpha 1, thymosin 5, etc.) within 6 months before the screening, and the course of treatment was more than 2 weeks;
- •Have taken hepatotoxic drugs (such as dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) within 6 months before screening, and the course of treatment was more than 2 weeks;
- •Currently or previously diagnosed or suspected with cirrhosis or liver cancer; or AFP > 50ng/ml;
- •Liver diseases caused by other causes: including alcoholic hepatitis, drug hepatitis, autoimmune liver disease;
- •Currently be infected of HAV, HCV, HDV, HEV, HIV and syphilis;
- •Have mental diseases, including but not limited to depression, anxiety, mania, schizophrenia;
- •Uncontrolled epilepsy;
- •Complicated with serious systemic diseases, including but not limited to: autoimmune diseases (such as psoriasis, systemic lupus erythematosus, etc.); not well controlled cardiovascular disease (such as high blood pressure, unstable angina pectoris, heart failure, etc.), endocrine system disease (such as thyroid function hyperfunction or loss, diabetes, etc.), respiratory system diseases (such as pulmonary infection, chronic obstructive pulmonary disease and pulmonary interstitial diseases, etc.), digestive system diseases (e.g., chronic colitis, etc.), kidney disease (such as chronic kidney disease, renal insufficiency, etc.), blood system diseases (such as autoimmune anemia, hemophilia, etc.); currently or previously diagnosed or suspected with malignant tumor;
- •Fundus diseases, such as not well controlled retinopathy, etc.;
- •Laboratory neutrophil count<1.5×109/L; platelet count <90×109/L;
- •Prothrombin time was extended by more than 3 seconds compared with the upper limit of normal reference value (ULN);
- •ALT>1.5×ULN; TBIL>2×ULN; SCR>1.5×ULN; serum creatine kinase >3×ULN; ALB<35g/L;
- •ANA>1:1000, anti-smooth muscle antibody>1:1000, thyrotropic hormone receptor antibody >2×ULN;
- •Allergic constitution or allergic to experimental drugs and excipients;
- •Plan to receive or have already had an organ transplant;
- •Participated in any clinical trial or taken any IMP (investigational medical product) within 3 months prior to the trial;
- •Other cases that could not be enrolled in the judgement of the investigators.
结局指标
主要结局
All the observed or reported AEs (adverse events)
时间窗: through study completion, an average of 60 weeks
observe and record all the AEs of patients during the clinical trial and determine their correlation with the investigational medical product
HBsAg change
时间窗: Day106 (Week15), Day211 (Week30), Day316 (Week45), Day337 (Week48), Day421 (Week60) after administration
evaluate the HBsAg change from the baseline to evaluate the efficacy of T101
次要结局
- Negative convention rate of HBsAg(Day316 (Week45), Day337 (Week48), Day421 (Week60) after administration)
- Positive convention rate of HBsAb(Day316 (Week45), Day337 (Week48), Day421 (Week60) after administration)
- The percentage of Subjects' HBsAg decrease ≥ 1 log(Day106 (Week15), Day211 (Week30), Day316 (Week45), Day337 (Week48), Day421 (Week60) after administration)
- The percentage of Subjects' HBsAg decrease ≥ 0.5 log(Day106 (Week15), Day211 (Week30), Day316 (Week45), Day337 (Week48), Day421 (Week60) after administration)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06668961Sichuan Baili Pharmaceutical Co., Ltd.48
招募中
2 期
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerTriple-Negative Breast CancerNCT06492005Mabwell (Shanghai) Bioscience Co., Ltd.160
已完成
2 期
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast CancerLocally Advanced Breast CancerMetastatic Breast CancerNCT05021900Rhizen Pharmaceuticals SA40
尚未招募
2 期
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.Active Systemic Juvenile Idiopathic ArthritisNCT05925452Changchun GeneScience Pharmaceutical Co., Ltd.30
已完成
2 期
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic Leukemia (B-CLL)NCT00328198Genzyme, a Sanofi Company86